Baker R R
Surg Clin North Am. 1978 Aug;58(4):681-91. doi: 10.1016/s0039-6109(16)41581-1.
The clinical assessment of patients with Stages I and II breast cancer is outlined in Figure 1. A chest x-ray film and serum alkaline phosphatase are the only routine studies indicated. If the serum alkaline phosphatase is abnormal in the presence of otherwise normal liver function studies, a bone scan, liver scan, and CEA should be obtained. Areas of increased radioactivity on bone scan are always evaluated by additional radiographs and in some cases tomograms. The majority of focal areas of increased radioactivity will demonstrate radiographic evidence of benign bone lesions, predominantly degenerative joint disease. Only those focal areas of increased radioactivity that are normal on x-ray film or show radiographic evidence of metastases are considered to be positive for metastatic disease. The results of the liver scan are correlated with the level of CEA. Focal areas of decreased radioactivity associated with a CEA greater than 5 ng per ml are considered to be metastases. In the absence of elevation of the CEA, focal areas of increased radioactivity should be biopsied prior to any further considerations as to definitive therapy. The clinical assessment of patients with Stage III disease is outlined in Figure 2. Patients with this stage of disease have a much greater chance of having clinically occult metastases of sufficient size to be detected by chest x-ray film, serum alkaline phosphatase, and bone scan. If the serum alkaline phosphatase is abnormal, a liver scan and CEA are obtained in an effort to detect liver metastases. The same sequence of events is then followed as suggested for patients with Stages I and II disease. Several new techniques of detecting occult metastases are being evaluated. Biomarkers are the subject of another article in this volume. The use of computerized axial tomography is also being evaluated as a means of detecting lung, liver, and mediastinal metastases. The results of these initial clinical trials should be carefully followed.
图1概述了I期和II期乳腺癌患者的临床评估。胸部X光片和血清碱性磷酸酶是仅有的常规检查项目。如果血清碱性磷酸酶异常而肝功能检查其他方面正常,则应进行骨扫描、肝脏扫描和癌胚抗原(CEA)检测。骨扫描放射性增强的区域总是要通过额外的X光片进行评估,在某些情况下还要进行断层扫描。大多数放射性增强的局灶性区域将显示出良性骨病变的影像学证据,主要是退行性关节病。只有那些在X光片上正常或显示有转移影像学证据的放射性增强局灶性区域才被认为是转移性疾病阳性。肝脏扫描结果与CEA水平相关。CEA大于5 ng/ml且伴有放射性减低的局灶性区域被认为是转移灶。在CEA未升高的情况下,对于放射性增强的局灶性区域,在考虑任何确定性治疗之前应进行活检。图2概述了III期疾病患者的临床评估。处于该疾病阶段的患者发生临床隐匿性转移的可能性要大得多,这些转移灶的大小足以通过胸部X光片、血清碱性磷酸酶和骨扫描检测出来。如果血清碱性磷酸酶异常,则进行肝脏扫描和CEA检测以试图发现肝转移。然后按照针对I期和II期疾病患者建议的相同流程进行。几种检测隐匿性转移的新技术正在评估中。生物标志物是本卷另一篇文章的主题。计算机断层扫描的应用也正在作为一种检测肺、肝和纵隔转移的方法进行评估。这些初步临床试验的结果应密切关注。